ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma

Table 4

Joint-effects analysis of the combination of ARMCX1 and ARMCX2.

Items	Cases (total )	No. of events (%)	MST (days)	Crude	Crude HR (95% CI)	Adjusted	Adjusted HR (95% CI)
Group 1	143	46 (32.2%)	1686	0.007	0.600 (0.414-0.870)	0.003	0.563 (0.384-0.825)
Group 2	65	27 (41.5%)	766	0.549	0.873 (0.559-1.362)	0.506	0.854 (0.537-1.358)
Group 3	143	71 (49.7%)	762	0.025	Ref.	0.012	Ref.

Abbreviations: MST: median survival time; Ref.: reference; HR: hazard ratio; 95% CI: 95% confidence interval; Notes: Adjusted , adjustment for age and tumor stage.